I now have comprehensive data from multiple authoritative anesthesia textbooks. Here is the full synthesis:
Midazolam — Doses for Premedication, Anxiolysis & Sedation
Mechanism & Clinical Profile
Midazolam is a water-soluble benzodiazepine that undergoes conformational change at physiological pH, becoming highly lipophilic. It acts as a GABA-A receptor agonist, augmenting chloride channel opening frequency. Key clinical effects:
- Anxiolysis
- Anterograde amnesia (retrograde memory unaffected)
- Sedation / hypnosis
- Anticonvulsant
- Minimal cardiovascular and respiratory depression (at clinical doses)
- Reversible with flumazenil
Peak IV effect: 2–3 minutes | Elimination half-life: 1.8–4 hours
Dosing by Indication
1. Preoperative Premedication
| Route | Population | Dose | Notes |
|---|
| Oral | Adults | 7.5–15 mg | Most common oral dose range |
| IV | Adults | 1–2.5 mg increments (titrated) | Given within 1 hour of induction |
| IM | Adults | 0.07–0.15 mg/kg | Well-absorbed IM; peak in ~30 min |
| Oral | Children | 0.5 mg/kg (max 15 mg) | Sedation/anxiolysis within ~20 min |
| Intranasal | Children | 0.2–0.3 mg/kg | Effective preoperative sedation |
| Buccal | Children | 0.07 mg/kg | |
| Sublingual | Children | 0.1 mg/kg | |
| Rectal | Children | 0.5 mg/kg | |
| IV | Children | 0.05–0.1 mg/kg | |
Factors influencing dose: age, ASA physical status, level of anxiety, type and duration of surgery. Doses should be reduced in the elderly.
2. Anxiolysis (Prior to Regional or General Anesthesia)
| Route | Dose | Notes |
|---|
| IV | 0.05–0.1 mg/kg | "Nearly ubiquitous" for preoperative anxiolysis before GA or regional |
| IV (incremental) | ~1–2 mg IV titrated | Standard adult incremental anxiolytic dose |
3. Procedural / Conscious Sedation
| Indication | Route | Dose | Notes |
|---|
| General procedural sedation | IV | 0.01–0.1 mg/kg (titrated) | Titrate to dysarthria or adequate sedation |
| Moderate sedation (surgical/diagnostic) | IV | 0.02–0.04 mg/kg (~1–2 mg) bolus | Barash Table 30-7: bolus prior to stimulus |
| Cardioversion | IV | 0.15 mg/kg (≥5 mg for average adult) | Induction ~2 min after dose |
| Emergency sedation | IV | 0.05 mg/kg | Per Rosen's Emergency Medicine |
Titration endpoint: adequate sedation or dysarthria. Onset rapid; time to peak effect 2–3 minutes IV. Duration is dose-dependent.
4. Anesthesia Induction
| Route | Dose | Notes |
|---|
| IV | 0.1–0.4 mg/kg | Higher end for induction of general anesthesia |
| IV (Barash) | 0.1–0.3 mg/kg | Duration of action 15–20 min |
5. ICU Sedation (Infusion)
Midazolam infusions provide continuous sedation comparable to propofol; however, extubation and recovery time are shorter with propofol. The active metabolite (1-hydroxymidazolam) accumulates with prolonged infusions, extending duration. Context-sensitive half-time increases with infusion duration — a key limitation.
Dose Equivalence Comparison
| Drug | Equivalent Dose (mg) | Oral Peak (h) | Elimination t½ (h) |
|---|
| Diazepam | 10 | 1–1.5 | 20–40 |
| Lorazepam | 1–2 | 2–4 | 10–20 |
| Midazolam | 3–5 | 0.5–1 | 1–4 |
Pharmacokinetic Summary
| Parameter | Value |
|---|
| Volume of distribution | 1–3.1 L/kg |
| Protein binding | 94% |
| Clearance | 6.4–11 mL/kg/min |
| Redistribution half-life | 7–15 min |
| Elimination half-life | 1.8–2.6 h (mean ~3 h) |
| Active metabolite | 1-hydroxymidazolam (~20% potency) |
Special Considerations
- Elderly patients: Reduce doses — pharmacodynamic sensitivity is increased; elimination half-life may extend to 4 hours.
- Hepatic/renal dysfunction: Clearance reduced; metabolite accumulates with infusions.
- Synergism: Combination with opioids produces synergistic CNS depression; with ketamine, interaction is additive. Dose reduce both agents when combined.
- Respiration: Minimal respiratory effects at clinical premedication doses, even up to 1.0 mg/kg (max 20 mg) in adults, but monitor when combined with other CNS depressants.
- Pediatric advantage: Positive behavioral effects noted up to 1 week postoperatively with oral midazolam premedication.
- Reversal: Flumazenil available for excessive sedation or respiratory depression.
Sources: Miller's Anesthesia 10e, p. 2528–2530 | Morgan & Mikhail's Clinical Anesthesiology 7e, p. 327 | Barash's Clinical Anesthesia 9e, pp. 1498–1500, 1805–1806, 2526 | Roberts & Hedges' Clinical Procedures in Emergency Medicine, p. 324